Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 03, 2015 3:35 PM ET

Biotechnology

Company Overview of Idera Pharmaceuticals, Inc.

Company Overview

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and gene silencing oligonucleotide (GSO) technology. The company’s lead drug candidate includes IMO-8400, which is in Phase 1/2 clinical trials for the treatment of Waldenström’s Macroglobulinemia, diffuse large B-cell lymphoma, and Duchenne muscular dystrophy, as well as in Phase 2 clinical trial for the treatment of dermatomyositis. Its p...

167 Sidney Street

Cambridge, MA 02139

United States

Founded in 1989

45 Employees

Phone:

617-679-5500

Fax:

617-679-5592

Key Executives for Idera Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 51
Total Annual Compensation: $50.0K
Chief Financial Officer, Senior Vice President of Operations and Treasurer
Age: 54
Total Annual Compensation: $425.9K
President of Research and Director
Age: 61
Total Annual Compensation: $856.4K
Compensation as of Fiscal Year 2014.

Idera Pharmaceuticals, Inc. Key Developments

Idera Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Idera Pharmaceuticals, Inc. reported earnings results for the second quarter and six months ended June 30, 2015. For the quarter, revenues were $5,000 against $38,000 a year ago. Loss from operations was $12,776,000 against $8,329,000 a year ago. Net loss applicable to common stockholders was $12,719,000 or $0.11 per basic and diluted share against $8,426,000 or $0.10 per basic and diluted share a year ago. For the six months, revenues were $39,000 against $41,000 a year ago. Loss from operations was $25,299,000 against $17,302,000 a year ago. Net loss applicable to common stockholders was $25,200,000 or $0.23 per basic and diluted share against $17,572,000 or $0.22 per basic and diluted share a year ago.

Idera Pharmaceuticals, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-11-2015 03:05 PM

Idera Pharmaceuticals, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-11-2015 03:05 PM. Venue: Le Parker Meridian, 119 West 56th Street, New York, NY 10019, United States. Speakers: Louis J. Arcudi, Chief Financial Officer, Senior Vice President of Operations and Treasurer.

Idera Pharmaceuticals Appoints Mark J. Casey as General Counsel and Secretary of the Board of Directors

Idera Pharmaceuticals, Inc. has appointed Mark J. Casey as Senior Vice President, General Counsel and Secretary of the Board of Directors. Mr. Casey most recently served as Chief Administrative Officer, Senior Vice President, General Counsel and Secretary of Hologic Incorporated.

Similar Private Companies By Industry

Company Name Region
Biothera Holding Corp. United States
AndroScience Corporation United States
Clerio Vision Inc. United States
Affomix Corporation United States
ImmuneWorks, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Idera Pharmaceuticals, Inc., please visit www.iderapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.